
Please try another search
COPENHAGEN (Reuters) -Danish biotechnology company Bavarian Nordic on Wednesday lifted its sales outlook and now expects a smaller operating loss this year after signing a contract with an undisclosed country for the supply of its monkeypox vaccine.
Bavarian shares traded up 16% at 1019 GMT and have risen more than 40% since the company announced a similar vaccine supply deal with an undisclosed country on May 19. The stock is down 28% this year.
"We have rapidly adapted to this unprecedented situation and are working closely with other governments to make vaccines available as fast as possible to mitigate the situation," CEO Paul Chaplin said in a statement.
The firm is currently in discussions with several other countries about potential supply agreements for its Imvanex monkeypox vaccine, which is branded Jynneos in the United States.
Germany on Tuesday announced it had ordered 40,000 doses of Bavarian's vaccine, but the firm has not confirmed whether it has entered any deal with Germany.
Bavarian now expects revenue to be between 1.3 and 1.5 billion Danish crowns ($187-$215 million), up from a previous estimate in the range of 1.1 and 1.4 billion.
It also raised its expectations for earnings before interest, tax and amortisation (EBITDA) to a loss of between 1 and 1.2 billion, up from a previous estimate of a loss of 1-1.3 billion.
Global health officials have tracked more than 200 suspected and confirmed cases of the usually mild viral infection in 19 countries since early May.
($1 = 6.9698 Danish crowns)
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.